Table 1 Patient’s clinical characteristics (N = 146).
Variables | No. of patients | % |
|---|---|---|
Median age, years (range) | 59.5 (28.0–84.0) | |
Sex | ||
Male | 85 | 58.2 |
Female | 61 | 41.8 |
Histologic subtypes | ||
Nodal MZL | 18 | 12.3 |
MALT lymphoma | 125 | 85.6 |
Splenic MZL | 3 | 2.1 |
ECOG PS | ||
0–1 | 131 | 89.7 |
≥ 2 | 15 | 10.3 |
Ann Arbor stage | ||
II | 25 | 17.1 |
III–IV | 121 | 82.9 |
Increased LDH | 34 | 23.3 |
Bone marrow involvement | 51 | 34.9 |
Extranodal site involvement | 128 | 87.7 |
Extranodal site > 1 | 51 | 34.9 |
Extranodal site | ||
Ocular | 26 | 17.8 |
Lung | 30 | 20.5 |
GI tract | 38 | 26.0 |
Spleen | 17 | 11.6 |
Bone | 3 | 2.1 |
IPI risk group | ||
Low (0–1) | 43 | 29.5 |
Low-intermediate (2) | 51 | 34.9 |
High-intermediate (3) | 36 | 24.7 |
High (4–5) | 16 | 11.0 |
MALT-IPI | ||
Low (0) | 21 | 14.4 |
Intermediate (1) | 85 | 58.2 |
High (2–3) | 39 | 26.7 |
First-line treatment | ||
R-CVP | 132 | 90.4 |
R-CHOP | 9 | 6.2 |
R-B | 5 | 3.4 |
